





An audit of electron microscopy in the diagnosis of focal
segmental glomerulosclerosis: are current pathological
techniques missing important abnormalities in the glomerular
 basement membrane? [version 1; peer review: 1 approved, 1
approved with reservations]

























































 26 Jul 2019,  :1204 (First published: 8
)https://doi.org/10.12688/f1000research.19997.1
 07 Nov 2019,  :1204 (Latest published: 8
)https://doi.org/10.12688/f1000research.19997.2
v1
Page 1 of 12
F1000Research 2019, 8:1204 Last updated: 13 NOV 2019
 
 Justin Davis ( )Corresponding author: justinbdavis19@gmail.com









 © 2019 Davis J  . This is an open access article distributed under the terms of the  , whichCopyright: et al Creative Commons Attribution License
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 Davis J, Tjipto A, Hegerty K and Mallett A. How to cite this article: An audit of electron microscopy in the diagnosis of focal segmental
glomerulosclerosis: are current pathological techniques missing important abnormalities in the glomerular basement membrane?
 F1000Research 2019,  :1204 ([version 1; peer review: 1 approved, 1 approved with reservations] 8
)https://doi.org/10.12688/f1000research.19997.1
 26 Jul 2019,  :1204 ( ) First published: 8 https://doi.org/10.12688/f1000research.19997.1
Page 2 of 12
F1000Research 2019, 8:1204 Last updated: 13 NOV 2019
Abbreviations
Chronic kidney disease (CKD); end stage kidney disease 
(ESKD); focal segmental glomerulosclerosis (FSGS); glomeru-
lar basement membrane (GBM); not otherwise specified (NOS); 
thin basement membrane nephropathy (TBMN).
Introduction
Focal segmental glomerulosclerosis (FSGS) is a pathological 
diagnosis which underpins a variety of progressive renal dis-
eases that commonly result in proteinuria, chronic kidney disease 
(CKD) and potential end stage kidney disease (ESKD) requir-
ing renal replacement therapy1. FSGS occurs in either a primary. 
secondary, or genetic form. Primary FSGS is thought to be 
largely immunological in nature perhaps driven by an elusive 
permeability factor and secondary FSGS caused by compensa-
tory hyperfiltration due to a previous glomerular injury2. In recent 
years there has been a greater appreciation of the contribution 
of underlying genetic causes of this histological pattern. Many 
of these genetic aetiologies for FSGS have potential clinical sig-
nificance for at-risk family members, subsequent genetic counsel-
ling, future living related kidney transplantation and therapeutics 
including potential avoidance of immunosuppressive therapies 
otherwise used for primary immunologically-mediated FSGS. 
Although initial focus has been on genes that are involved in the 
maintenance of podocyte structure and function it has become 
apparent that abnormalities in genes responsible for the struc-
tural integrity of the glomerular basement membrane (GBM) 
may underpin a significant minority of cases of adult-onset FSGS3. 
Variants in COL4A3, COL4A4 and COL4A5, which encode 
the α3, α4 and α5 chains of collagen IV, respectively, the major 
constituent of the GBM, previously linked to both Alport syn-
drome and thin basement membrane nephropathy (TBMN), may 
also underlie cases of FSGS4. This suggestion has biological 
plausibility. Podocytes, the glomerular epithelial cells respon-
sible for maintenance of the filtration barrier of the glomerulus 
through which plasma is ultrafiltrated, are not only a source for 
the α-chains secreted to form the GBM but also are required to 
be anchored to this structure in order to maintain the afore-
mentioned filtration barrier2,5. It is not inconceivable then that 
inherited structural abnormalities of the GBM may lead to 
subsequent podocyte dysfunction and ultimately the lesion 
histologically characterised as FSGS. 
The relationship between the three renal conditions intertwined 
around variants in the collagen IV genes, Alport syndrome, 
TBMN, and FSGS is complex and incompletely understood. Whilst 
previously it was believed that patients heterozygous for variants 
in COL4A3 and COL4A4 would develop TBMN with persist-
ent microscopic haematuria and an otherwise benign prognosis, 
this traditional thinking has been overturned by the discovery 
that some pedigrees with these variants will go on to develop 
significant proteinuria, FSGS lesions and the potential for pro-
gressive CKD or ESRD6,7. More recently, targeted gene sequenc-
ing of adults thought to have primary FSGS or steroid resistant 
nephrotic syndrome (the paediatric equivalent) found that patho-
genic or likely pathogenic variants in collagen IV genes were 
present in up to 38% of families with familial FSGS, and 3% 
of those with sporadic FSGS3,8. These findings highlight the 
importance of considering variants in these genes in the diag-
nosis and subsequent management of patients found to have 
FSGS histologically. 
FSGS is a clinicopathological diagnosis that is made on the 
review of renal tissue obtained by percutaneous biopsy. This 
tissue is processed and subjected to several different staining 
techniques and methods of microscopy, including light, immun-
ofluorescence and electron microscopy9. FSGS, suggested on light 
microscopy by the finding of focal, segmental lesions with scle-
rosis, and an increase in the glomerular matrix with obliteration 
of the capillary lumens only requires this finding in one glomeru-
lus and light microscopy to diagnose2. As such, some specimens 
may previously have not been sent for further processing and 
review with other techniques such as electron microscopy even 
though this histopathology has heterogenous causative aetiologies. 
The other potential renal lesions that may be caused by collagen 
IV gene variants, Alport syndrome and TBMN, cause thinning, 
lamellation and fraying of the GBM and may also be associ-
ated with podocyte foot process effacement, all of which require 
electron microscopy to visualise4. It should be noted that for 
Alport syndrome there are other techniques aside from elec-
tron microscopy available for identifying the diagnosis. Immu-
nostaining of a renal biopsy specimen for type IV collagen may 
demonstrate the absence of alpha 3,4 or 5 chains in up to two 
thirds of patients, or a skin biopsy may show an absence of an 
alpha 5 chain10,11, in addition to the aforementioned genetic test-
ing. Such absence by immunostaining does not appear be present 
in FSGS12. Given that the pathological diagnosis of FSGS does 
not routinely require electron microscopy it is therefore conceiv-
able that GBM lesions potentially associated with an underlying 
collagen 4 variant may have been missed. This represents an 
opportunity to audit our prior clinical behaviour to see if our multi-
disciplinary diagnostic practice may require improvement. We 
conducted a retrospective audit of prior renal biopsy results 
in two tertiary centres to see how many of those that had been 




Our study was a retrospective cohort analysis across two 
tertiary hospital sites involving the review of prior renal biopsy 
results that had been given the histological diagnosis of FSGS on 
light microscopy and how many of these samples subsequently 
went on to be processed for electron microscopy. In addition, 
of those samples that were subjected to electron microscopy, we 
reviewed how many displayed evidence of a potential collagen 
IV disorder. This project had ethics approval through Barwon 
Health’s Research Ethics Governance and Integrity unit and the 
Royal Brisbane and Women’s Hospital Human Research and 
Ethics Committee (HREC 18/131 and HREC/18/QRBW/258, 
respectively). Participants consent was waived by both ethics 
committees due to the negligible risk nature of data acquisition 
via retrospective datasets already maintained on electronic 
health records at both institutions. 
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Eligibility criteria
Patients aged over the age of 18 who received a histologi-
cal diagnosis of FSGS on native kidney biopsy during the time 
period of January 1st 2008 until July 31st 2018 at the first par-
ticipating hospital and from the 1st of October 2013 until the 
29th of December 2018 at the second were eligible to be included 
in the retrospective audit. Participants were excluded from the 
audit if they were less than 18 years of age, underwent kidney 
transplant biopsy, were defined clinically to have secondary 
FSGS as opposed to primary disease, received their diagnosis of 
FSGS or underwent a renal biopsy and pathological review 
outside of the prespecified time period for each institution. 
Sample treatment
Samples for biopsy were placed in the following fixatives for 
processing; formalin for light microscopy, saline soaked gauze 
with freezing for immunofluorescence, and glutaraldehyde for 
electron microscopy. Samples for light microscopy are embed-
ded and sectioned at 2- to 3-µm thickness with hematoxylin- 
eosin, Jones silver, periodic acid-schiff and trichrome staining 
performed. Immunofluorescence samples are sectioned within 
a cryostat and placed on prelabelled air-dried slides of the antigen 
in question. Electron microscopy tissue is processed into plas-
tic, trimmed, cut into a 1-µm section and stained with toludine 
blue. The images are reviewed in a digital medium13. 
Identification of participants and data analysis
A search strategy was developed for this retrospective cohort 
study to identify appropriate patients through local electronic 
medical record systems using the search term ‘focal segmen-
tal glomerulosclerosis’ with the AND operator to combine with 
‘glomerulonephritis’ or ‘hereditary nephritis’. These patient results 
were subsequently reviewed for evidence of a previous percu-
taneous renal biopsy and report. The data were independently 
extracted from the included patients by the primary reviewer and 
collated in a Microsoft Excel document that included informa-
tion on age, primary diagnosis, included use of electron micros-
copy and any changes that may be consistent with an underlying 
collagen disorder including thinning, lamellation and fraying 
of the GBM. The data extracted was verified by the other three 
co-authors with all discrepancies resolved through discussion 
and consensus. 
Results
Participant information and diagnoses
From January 2008 through to July 2018 at the first centre and 
October 2013 until December 2018 at the second, a total of 43 
patients were identified as having primary FSGS. The baseline 
characteristics of the study cohort are provided in Table 1. The 
median age was 49 years and the patients were predominantly 
male (55%). The most common underlying histological diag-
nosis reported in the renal biopsy clinical pathology reports 
was FSGS not otherwise specified (NOS), followed by famil-
ial FSGS with no underlying genetic disorder ascertained. There 
were small numbers of the cellular, collapsing, perihilar and tip 
FSGS variants noted. The two most common stages of CKD at 
the time of presentation were I and III. The results extracted and 
analyses in this study are available as Underlying data14.
Use of electron microscopy
Of the 43 patients identified, samples from 30 underwent elec-
tron microscopy after initial light microscopy and immun-
ofluorescence. Two of these samples showed signs on electron 
microscopy that might be consistent with an underlying collagen 
IV glomerular basement membrane disorder. Microscopic hae-
maturia was not noted in either of these two patients. Of the 13 
samples that did not undergo electron microscopy, four had no 
glomeruli present within the processed core. The remaining 
nine samples had no documented reason.
The overall percentage of biopsy samples for which data were 
available that were not subjected to electron microscopy was 
30%, of which close to 21% had no documented reason for not 
undergoing electron microscopy. The annualised rate of biopsy 
samples that were not subjected to electron microscopy varied 
with time (Figure 1). The number of biopsy reports available for 
analysis prior to 2013 was only one per year at most; however, 
from 2013 onwards the rate progressively increased to between 
3 and 11 cases of FSGS diagnosed at histopathology between 
Table 1. Demographic and clinical characteristics of the 
patients at baseline.
CHARACTERISTIC Value, n (%) (unless 
indicated)
Age, years* Median (range) 49.95 (23–88)
Sex 
   Male 24 (55.81)
   Female 19 (44.18)
Underlying diagnosis
   FSGS NOS 31 (72.09)
   FSGS cellular variant 2 (4.65)
   FSGS collapsing variant 1 (2.32)
   FSGS Familial 3 (6.97)
   FSGS Perihilar 3 (6.97)
   FSGS Tip 3 (6.97)
Electron microscopy report 
available for biopsy?
   Yes 30 (69.76)
   No 13 (30.23)
Collagen disorder suggested 2 (2.81)
Stage at diagnosis 
   I 12
   II 9
   III 12
   IV 8
   V 2
   Unknown 0
*Values given as median (range).
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the two institutions per year. The annualised rate of electron 
microscopy from 2013 onwards varied each year, ranging from 
50 to 87%. Overall 30% of biopsy samples did not receive elec-
tron microscopy. The overall rate of electron microscopy did 
not significantly change across the study period between the 
two centres.
Discussion
This retrospective cohort analysis demonstrated that about 
two-thirds of native kidney biopsy samples across two institu-
tions that were deemed to have primary FSGS underwent subse-
quent electron microscopy. Of those that did, two were reported 
to have characteristics that might be consistent with an underly-
ing collagen IV disorder. In both samples, electron microscopy 
revealed a diffusely thin GBM, with the second additionally 
identifying early focal splitting of the GBM. The first sample 
was suggested to be consistent with TBMN whereas there was 
no pathological comment made about the second. FSGS (NOS) 
was the most common lesion described in this study, which is 
consistent with prior reports2. Notably, close to one in three 
cases of primary FSGS were not proceeding to electron micros-
copy despite an indication to do so and 1 in 20 cases within our 
cohort had structural changes that were consistent with an under-
lying collagen IV variant. Whilst some samples were unable 
to undergo electron microscopy due to a lack of glomeruli in 
the biopsy core, in the majority of the others it is unclear why 
subsequent electron microscopy did not occur. The annualised 
rate of biopsy samples not subjected to electron microscopy 
varied by year, but on average around one in three samples 
were not subjected to electron microscopy despite receiving a 
histological diagnosis of FSGS. 
Curiously, neither of the two patients in whom electron micro-
scopy was suggestive of an underlying collagen IV disorder was 
noted to have haematuria on their urinalysis at the time of pres-
entation. Both of these samples were noted to have a thin 
basement membrane on electron microscopy, with focal split-
ting noted in one with an average thickness of 230.72 nm given. 
Unfortunately, due to the retrospective nature of this study 
we were unable to send any samples for immunostaining of 
collagen IV. 
There is an increasing body of evidence indicating that inherit-
able variants in collagen IV genes may underlie a proportion 
of cases of FSGS, with up to 12.5% cases of autosomal domi-
nant FSGS attributable to COL4A3 in some cohorts15. Not 
subjecting these renal biopsy samples to electron microscopy 
represents a potential gap in the investigation and subsequent 
management of such patients given they are much less likely to 
respond to immunosuppressive therapy16 which has otherwise 
been classically indicated.
This study was designed as a retrospective cohort study 
looking at the number of samples sent for electron micros-
copy, as well as any potential changes which might be consistent 
with a collagen IV glomerular basement membrane disorder. It 
is important to recognise that not all groups have found the char-
acteristic changes associated with the collagen IV disorders 
such as Alport’s Syndrome or TBMN on electron microscopy. 
One study described the typical pathological changes of FSGS 
but not the glomerular basement membrane abnormalities char-
acterising Alport syndrome or TBMN in patients known to have 
variants in either COL4A3 or COL4A47. It is thus possible that a 
lack of classical findings for a collagen IV glomerular basement 
membrane disorder may have accounted for the low number 
of those with GBM features on electron microscopy consistent 
with a collagen 4 disorder noted within our study. Indicating 
against this, however, another study suggested that biopsy samples 
Figure 1. Annualised rate of biopsy samples subjected to electron microscopy.
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from patients with the classical features of Alport Syndrome or 
TBMN showed podocyte detachment which might be expected 
and subsequently cause FSGS-type lesions4. Other studies which 
have looked at electron microscopy in FSGS cases have similarly 
found low numbers of abnormalities that may be consistent with 
an underlying collagen 4 disorder3,8, which suggests the over-
all number of abnormalities to be found via electron microscopy 
may be low.
The process by which variants within the collagen IV genes 
might cause FSGS remains unclear, particularly given their clear 
association with Alport Syndrome and TBMN. One proposal 
is that the ultrastructural changes induced by the collagen IV 
variants, perhaps under the influence of modifier genes such as 
laminin, result in impaired podocyte attachment to the glomerular 
basement membrane which leads to accelerated podocyte detach-
ment, subsequent foot process effacement as a response to the 
increased shear stress induced by the denuded basement mem-
brane and at a critical level of podocyte loss collapse of the 
capillary network with the appearance of the classical segmen-
tal sclerotic lesion2,4,17. It also remains unclear as to whether the 
changes of FSGS are a secondary process occurring in those with 
TBMN or whether the collagen 4 variants are capable of caus-
ing primary FSGS7,18. FSGS occurring as a secondary process to 
other basement membrane abnormalities may explain why immu-
nosuppressive therapy has traditionally been less effective in 
inherited forms of FSGS, although there are case reports of the 
successful use of the calcineurin inhibitor cyclosporine for some 
patients harbouring inheritable collagen 4 disorders6.
In summary, this study has found that not all biopsy samples 
that had primary FSGS as a histological diagnosis were sub-
jected to subsequent electron microscopy. This may have poten-
tially led to inadvertently overlooking characteristic basement 
membrane abnormalities, which may suggest an underlying and 
heritable collagen IV disorder. These findings reflect an oppor-
tunity to change practice in order to better investigate, counsel 
and provide clinical management to these and future patients.
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Underlying data
Figshare: Davis et al. FSGS biopsy audit.xlsx. https://doi.
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Data are available under the terms of the Creative Commons 
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